CN Patent

CN118924758A — Btk抑制剂的用途和单剂量药物

Assigned to Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co · Expires 2024-11-12 · 2y expired

What this patent protects

本发明公开了一种式(I)所示的化合物或式(I)所示化合物的立体异构体、互变异构体、溶剂化物、药学上可接受的盐在制备药物中的用途，所述药物用于治疗和/或预防免疫系统疾病。上述式(I)所示的化合物或式(I)所示化合物的立体异构体、互变异构体、溶剂化物、药学上可接受的盐作为BTK激酶抑制剂，其可有效治疗和/或预防免疫系统疾病。

USPTO Abstract

本发明公开了一种式(I)所示的化合物或式(I)所示化合物的立体异构体、互变异构体、溶剂化物、药学上可接受的盐在制备药物中的用途，所述药物用于治疗和/或预防免疫系统疾病。上述式(I)所示的化合物或式(I)所示化合物的立体异构体、互变异构体、溶剂化物、药学上可接受的盐作为BTK激酶抑制剂，其可有效治疗和/或预防免疫系统疾病。

Drugs covered by this patent

Patent Metadata

Patent number: CN118924758A
Jurisdiction: CN
Classification: —
Expires: 2024-11-12
Drug substance claim: No
Drug product claim: No
Assignee: Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.